Literature DB >> 16406150

Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease.

Sumihiro Maeda1, Naruhiko Sahara, Yuko Saito, Shigeo Murayama, Atsushi Ikai, Akihiko Takashima.   

Abstract

Development of neurofibrillary tangles (NFTs) is a pathological hallmark in various neurodegenerative disorders including Alzheimer's disease (AD). Recently, we identified a granular tau oligomer having a pre-filamentous structure. To determine the role of this oligomer in NFT formation, we quantified the amount of granular tau oligomer in 21 frontal cortex samples, each displaying varying degrees of Braak-staged NFT pathology. Here we report that granular tau oligomer levels in frontal cortex were significantly increased, even in brains displaying Braak-stage I neuropathology, a stage at which clinical symptoms of AD and NFTs in frontal cortex are believed to be absent. This suggests that increases in granular tau oligomer levels occur before NFTs form and before individuals manifest clinical symptoms of AD. Increased granular tau oligomer levels, therefore, may lead to NFT formation in frontal cortex, eventually leading to the development of AD. Thus, increases in granular tau oligomer levels may represent a very early sign of NFT formation and AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406150     DOI: 10.1016/j.neures.2005.11.009

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  114 in total

1.  Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss.

Authors:  Tetsuya Kimura; Tetsuya Fukuda; Naruhiko Sahara; Shunji Yamashita; Miyuki Murayama; Tatsuya Mizoroki; Yuji Yoshiike; Boyoung Lee; Ioannis Sotiropoulos; Sumihiro Maeda; Akihiko Takashima
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

3.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

4.  Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau.

Authors:  Anna Pavlova; Chi-Yuan Cheng; Maia Kinnebrew; John Lew; Frederick W Dahlquist; Songi Han
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

5.  Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Authors:  Julia Gerson; Diana L Castillo-Carranza; Urmi Sengupta; Riddhi Bodani; Donald S Prough; Douglas S DeWitt; Bridget E Hawkins; Rakez Kayed
Journal:  J Neurotrauma       Date:  2016-04-22       Impact factor: 5.269

6.  Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants.

Authors:  Erin E Congdon; Sohee Kim; Jonathan Bonchak; Tanakorn Songrug; Anastasios Matzavinos; Jeff Kuret
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

7.  Rho-kinase ROCK inhibitors reduce oligomeric tau protein.

Authors:  Tadanori Hamano; Norimichi Shirafuji; Shu-Hui Yen; Hirotaka Yoshida; Nicholas M Kanaan; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Youshi Fujita; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Neurobiol Aging       Date:  2019-12-16       Impact factor: 4.673

Review 8.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.